Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).

AIMS: SUSTAIN 10 compared the efficacy and safety of the anticipated most frequent semaglutide dose (1.0mg) with the current most frequently prescribed liraglutide dose in Europe (1.2mg), reflecting clinical practice. METHODS: In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg. Primary and confirmatory secondary endpoints were changes in HbA1c and body weight from baseline to week 30, respectively. RESULTS: Mean HbA1c (baseline 8.2%) decreased by 1.7% with semaglutide and 1.0% with liraglutide (estimated treatment difference [ETD] -0.69%; 95% confidence interval [CI] -0.82 to -0.56, P<0.0001). Mean body weight (baseline 96.9kg) decreased by 5.8kg with semaglutide and 1.9kg with liraglutide (ETD -3.83kg; 95% CI -4.57 to -3.09, P<0.0001). The proportions of subjects achieving glycaemic targets of<7.0% and=6.5%, weight loss of=5% and=10%, and a composite endpoint of HbA1c<7.0% without severe or blood glucose-confirmed symptomatic hypoglycaemia and no weight gain were greater with semaglutide vs liraglutide (all P<0.0001). Both treatments had similar safety profiles, except for more frequent gastrointestinal disorders (the most common adverse events [AEs]) and AEs leading to premature treatment discontinuation with semaglutide vs liraglutide (43.9% vs 38.3% and 11.4% vs 6.6%, respectively). CONCLUSION: Semaglutide was superior to liraglutide in reducing HbA1c and body weight. Safety profiles were generally similar, except for higher rates of gastrointestinal AEs with semaglutide vs liraglutide.

Toxoplasma seroepidemiology in women who intend to marry in Jahrom, Islamic Republic of Iran.

Infection with Toxoplasma gondii during pregnancy can lead to severe fetal sequelae. This cross-sectional study aimed to determine T. gondii seropositivity among a sample of young women in Jahrom, Islamic Republic of Iran. Four hundred and three young women with a mean age of 20.3 years who presented for pre-marriage laboratory testing were entered in the study. T. gondii antibodies (IgG and IgM) were measured using ELISA. Of the 403 women, 15% were seropositive for T. gondii antibodies (13% for IgG and 2% for IgM). Seropositivity for T. gondii IgG differed according to age groups but there was no significant difference (P = 0.83). IgM seropositivity showed the highest rate among women aged < 20 years. Many young women in Jahrom Province are susceptible to primary toxoplasmosis during pregnancy, therefore, appropriate educational programmes to improve knowledge in this population should be implemented to prevent toxoplasmosis-related congenital malformations.

Toxoplasma seroepidemiology in women who intend to marry in Jahrom, Islamic Republic of Iran

Infection with Toxoplasma gondii during pregnancy can lead to severe fetal sequelae. This cross-sectional study aimed to determine T. gondii seropositivity among a sample of young women in Jahrom, Islamic Republic of Iran. Four hundred and three young women with a mean age of 20.3 years who presented for pre-marriage laboratory testing were entered in the study. T. gondii antibodies [IgG and IgM] were measured using ELISA. Of the 403 women, 15% were seropositive for T. gondii antibodies [13% for IgG and 2% for IgM].Seropositivity for T. gondii IgG differed according to age groups but there was no significant difference [P = 0.83]. IgM seropositivity showed the highest rate among women aged < 20 years. Many young women in Jahrom Province are susceptible to primary toxoplasmosis during pregnancy, therefore, appropriate educational programmes to improve knowledge in this population should be implemented to prevent toxoplasmosis-related congenital malformations